ReNeuron’s AGM trading update contains no surprises. Data is expected from its CTX stem cell therapy candidate for stroke (Phase II), CTX stem cell therapy candidate for critical limb ischaemia (Phase I) and hRPC stem cell therapy candidate for retinitis pigmentosa (Phase I/II) in the next twelve months. Positive data from each would be a share price catalyst and offer significant upside potential. We remain at Buy and look forward to data over the coming year.
06 Sep 2016
N+1 Singer - ReNeuron Group - AGM trading update
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - ReNeuron Group - AGM trading update
ReNeuron Group plc (RENE:LON) | 3.0 0 0.0% | Mkt Cap: 1.74m
- Published:
06 Sep 2016 -
Author:
Sheena Berry -
Pages:
3
ReNeuron’s AGM trading update contains no surprises. Data is expected from its CTX stem cell therapy candidate for stroke (Phase II), CTX stem cell therapy candidate for critical limb ischaemia (Phase I) and hRPC stem cell therapy candidate for retinitis pigmentosa (Phase I/II) in the next twelve months. Positive data from each would be a share price catalyst and offer significant upside potential. We remain at Buy and look forward to data over the coming year.